BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

LifeScience Antibody Drug Conjugates

Biocytogen And Acepodia Advance Dual Payload Bispecific ADC Strategy Through Option Based Licensing Pact

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), announced that the companies have entered int...

January 12, 2026 | News

Sidewinder Therapeutics Secures Multi Target ADC Licensing Agreement With Lonza

Multi-target license agreement grants Sidewinder access to Lonza's clinically validated ADC platform Sidewinder's pipeline...

January 08, 2026 | News

Sichuan Kelun Biotech Secures NMPA IND Approval For SKB105 Antibody Drug Conjugate In Advanced Solid Tumours

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that its Investigational New Drug (IND) appli...

January 07, 2026 | News

Mabwell Doses First Patient Globally In Phase II Trial Of IL 11 Antibody For Pathological Scarring

Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the Phase II clinical trial of i...

January 01, 2026 | News

Senhwa Biosciences Advances CX 5461 Into ADC Combination Trial With Enhertu Backed By US NCI

Senhwa Biosciences has announced a significant clinical milestone with its investigational drug Pidnarulex CX 5461 advancing into a Phase 1...

December 30, 2025 | News

Alphamab Oncology Secures IND Acceptance In China For JSKN033 Phase II Cervical Cancer Study

Alphamab Oncology (Stock Code: 9966.HK) announced that the IND application for a Phase II clinical study of JSKN033 (a proprietary high-concentration subcu...

December 30, 2025 | News

ABL Bio Lands Strategic 55 Million Funding Boost To Fast Track Next Wave Of Breakthrough Antibody Therapies

Secured a total of 55 million in R&D funding, including 40 million in upfront payment and 15 million in equity investment - Accelerating R&D on co...

December 29, 2025 | News

Mabwell Secures US FDA IND Clearance For Anti ST2 Antibody In COPD

Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that it has received IND clearance fr...

December 26, 2025 | News

SN Bioscience Secures US FDA Orphan Drug Designation For SNB 101 In Gastric Cancer

SN Bioscience Inc. (CEO Young Hwan PARK) announced that the FDA had granted Orphan Drug Designation (ODD) on December 10 for gastric cancer (incl...

December 25, 2025 | News

CHITOSE And FUJIFILM Biosciences Form Strategic Alliance To Advance Biopharmaceutical Manufacturing

Collaboration formed to accelerate biopharmaceutical manufacturing combining high performing CHO-MK cells and GMP-manufactured culture media. Ch...

December 22, 2025 | News

GenSci, RTW And Yarrow Forge US Focused Biotech Partnership To Advance First In Class Thyroid Autoimmune Therapy

Collaboration to focus on building a leading, US-based biotech dedicated to addressing underserved patients impacted by autoimmune and endocrinology di...

December 17, 2025 | News

Akeso Secures FDA Clearance to Launch Global Phase III Gastric Cancer Trial of Cadonilimab

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced FDA approval to initiate COMPASSION-37/AK104-311 trial, a global multicenter Phase III trial in ...

December 15, 2025 | News

Mango Sciences Partners with ImmunoACT to Expand Access to NexCAR19 CAR-T Therapy in India

Mango Sciences, Inc., the Boston, US, and Bengaluru, IN-based data and AI company, announced a strategic partnership with ImmunoAdoptive Cell Therapy (Immu...

December 08, 2025 | News

Biocytogen Announces FDA IND Clearance for IDE034 Bispecific B7H3 PTK7 ADC Licensed to IDEAYA Biosciences

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision o...

December 08, 2025 | News

Stay Connected